The endocannabinoid signalling system was discovered because receptors in this system
are the targets of compounds present in psychotropic preparations of Cannabis sativa. The …

Endocannabinoids acting via CB 1 receptors (CB 1 R) play a critical role in regulating
energy homeostasis, which was the rationale for the pharmaceutical development of CB 1 R …

Drugs selectively targeting CB2 hold promise for treating neurodegenerative disorders,
inflammation, and pain while avoiding psychotropic side effects mediated by CB1. The …

Cannabinoid receptors type 1 (CB1) and 2 (CB2) are widely expressed in the human body,
and are attractive drug targets in the prevention and management of central nervous system …

Cannabinoids might be a suitable treatment for RA, but it is important to target the right
receptors in the right place. For clinical studies, we propose a combination of a CB 2 agonist …

Cannabinoid pharmacology has been intensely studied because of cannabis' pervasive
medicinal and non-medicinal uses as well as for the therapeutic potential of cannabinoid …

The endogenous cannabinoids anandamide and 2-arachidonoylglycerol bind to the
cannabinoid receptors of type 1 and 2. These receptors are also the binding sites for …

Cannabis sativa L. has garnered attention as a potential source for new antimicrobial
agents, particularly due to the increased prevalence of microbial resistance to conventional …

Neuropathic pain is maladaptive pain caused by injury or dysfunction in peripheral and
central nervous system, and remains a worldwide thorny problem leading to decreases in …

The G-protein-coupled cannabinoid receptor type 2 (CB2R) is a key element of the
endocannabinoid (EC) system. EC/CB2R signaling has significant therapeutic potential in …